CAJ | 학술논문

目的：研究 ER -α36（estrogen receptor - alpha 36）在乳腺癌组织中的表达状态及在乳腺癌发生、发展和临床预后中的作用。方法：选取河南省肿瘤医院乳腺科及郑州大学第一附属医院乳腺科2010年3月-2013年3月间653例乳腺癌组织，用 RT - PCR 技术和免疫组化技术检测组织中 ER -α36、ER -α66、PR 和Her -2的表达，分析 ER -α36的表达与上述指标及临床病理特征之间的关系。结果：ER -α36的总体表达率是40%（261/653）。在 Her -2阳性组织中的表达率63%（78/124），显著高于阴性组35%（183/529），P <0.05。在 ER -α66/ PR/ Her -2三阴性组织中的表达率66%（69/104），显著高于非三阴性组35%（192/549）， P <0.05。在 ER -α66阳性和阴性样本中及在 PR 阳性和阴性样本中的表达率，差异没有统计学意义（P>0.05）。在 III + IV 期乳腺癌组织中的阳性表达率54%（165/305），明显高于 I + II 期28%（96/348），P <0.05。在淋巴结转移阳性乳腺癌组织中的表达率55%（184/335），显著高于无转移组织24%（77/318），P <0.05。结论：ER -α36可能在乳腺癌的发生、发展及淋巴结转移过程中具有重要作用，并与 Her -2的表达、乳腺癌分期及淋巴结转移有关，有望成为新的肿瘤标记物及临床诊治的新靶点。
목적：연구 ER -α36（estrogen receptor - alpha 36）재유선암조직중적표체상태급재유선암발생、발전화림상예후중적작용。방법：선취하남성종류의원유선과급정주대학제일부속의원유선과2010년3월-2013년3월간653례유선암조직，용 RT - PCR 기술화면역조화기술검측조직중 ER -α36、ER -α66、PR 화Her -2적표체，분석 ER -α36적표체여상술지표급림상병리특정지간적관계。결과：ER -α36적총체표체솔시40%（261/653）。재 Her -2양성조직중적표체솔63%（78/124），현저고우음성조35%（183/529），P <0.05。재 ER -α66/ PR/ Her -2삼음성조직중적표체솔66%（69/104），현저고우비삼음성조35%（192/549）， P <0.05。재 ER -α66양성화음성양본중급재 PR 양성화음성양본중적표체솔，차이몰유통계학의의（P>0.05）。재 III + IV 기유선암조직중적양성표체솔54%（165/305），명현고우 I + II 기28%（96/348），P <0.05。재림파결전이양성유선암조직중적표체솔55%（184/335），현저고우무전이조직24%（77/318），P <0.05。결론：ER -α36가능재유선암적발생、발전급림파결전이과정중구유중요작용，병여 Her -2적표체、유선암분기급림파결전이유관，유망성위신적종류표기물급림상진치적신파점。
Objective:To study the expression status of ER - α36 in breast cancer tissue and its roles in the oc-currence,development,clinical prognosis of breast cancer. Methods:All 653 cases with breast cancer were selected from March 2010 to March 2013 in the Breast Department of Henan Cancer Hospital and the First Affiliated Hospital of Zhengzhou University. RT - PCR and immunohistochemistry was used to detect the expression of ER - α36,ER -α66,PR and Her - 2. The relationship between the expression of ER - α36,ER - α66,PR and Her - 2 and the patho-logical character was analyzed. Results:The expression rate of ER - α36 in all cases was 40%(261 / 653). The ex-pression rate of ER - α36 in Her - 2 positive tissues was 63%(78 / 124),which was significantly higher than that in the Her - 2 negative group(35% ,183 / 529)(P < 0. 05). The expression rate of ER - α36 in ER - α66 / PR/ Her - 2 negative tissues was 66%(69 / 104),which was significantly higher than that in the non - three - negative group (35% ,192 / 549)(P < 0. 05). The differences of ER - α36 expression rate between ER - α66 positive samples and negative samples or between PR positive and negative samples showed no statistical significance(P > 0. 05). The ex-pression rate of ER - α36 in stage III + IV breast cancer tissue was 54%(165 / 305),which was significantly higher than that in stage I + II breast cancer tissue(28% ,96 / 348)(P < 0. 05). The expression rate of ER - α36 in breast cancer tissue with lymph node metastasis was 55%(184 / 335),which was significantly higher than that in breast cancer tissue without lymph node metastasis(24% ,77 / 318)(P < 0. 05). Conclusion:The results indicate that ER- α36 may play an very important role in the occurrence,development and lymph node metastasis of breast cancer, and be associated with the expression of Her - 2,breast cancer staging and lymph node metastasis. ER - α36 is expec-ted to become a new tumor marker in clinical diagnosis and treatment target.